Business Wire

Diligent Launches Board Reporting for ESG, Providing Directors With Clear and Consistent Insight Into Climate Performance Amid CSRD and Upcoming SEC Climate Disclosure Requirements

Share

Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announced the launch of Board Reporting for ESG, a first-of-its-kind board dashboard that combines performance data with market intelligence to give a comprehensive view of an organization’s environmental, social and governance (ESG) posture. Built on the only platform that offers tools to support an organization through its entire GRC journey, Board Reporting for ESG can be tailored to capture an organization’s climate and other ESG data. This enables sustainability professionals to focus on the data that matters, delivering reporting in an easy-to-comprehend format for executive management and company directors.

“Collecting and organizing an overwhelming amount of climate data is challenging and presenting a clear and compelling story to the board is even harder,” said Amanda Carty, Managing Director of ESG & Data Intelligence at Diligent. “Board Reporting for ESG takes the guesswork out of climate reporting, equipping practitioners with the right information to share and allowing executives and board members to see the whole picture, so they spend less time trying to decipher complex information and more time focused on the right insights and data to drive the organization forward.”

Board Reporting for ESG benefits both functional leaders and board members, making data collection more efficient so sustainability professionals can bring unprecedented clarity to the c-suite and ultimately the boardroom. Functional leaders can customize templates to meet the unique needs of their organization or use out-of-the-box reporting templates to input the ESG performance data most important to corporate directors.

Key features include:

  • Board-ready reporting dashboards designed to provide insight into the relationship between company performance and stakeholder perception on sustainability and ESG.
  • Progress against carbon targets, peer benchmark disclosures and scope 1, 2 and 3 emissions from Diligent ESG, the market’s most comprehensive ESG solution.
  • ESG scores from Clarity AI and S&P Global, benchmarked against industry averages to provide insight into how an organization is measuring up against its competitors.
  • Best practices and training materials on presenting to the board, including access to Diligent’s industry leading Climate Leadership and ESG Leadership certifications.

"The SEC is pushing on boards to have quality oversight with depth of knowledge and you can't just be a generalist, you have to go get yourself educated and that's where Diligent can help directors,” said Catherine Lego, board director at Cirrus Logic and Guidewire Software.

To learn more about how Diligent can help your organization streamline board-level reporting on ESG and across your business, visit Diligent’s Board Reporting Toolkit.

About Diligent

Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Empowering more than 1 million users and 700,000 board members and leaders with a holistic view of their organization’s GRC practices so they can make better decisions, faster. No matter the challenge. Learn more at diligent.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For More Information:
Julia Hanbury
Senior Communications Manager, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye